B Ungar

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5304739/publications.pdf

Version: 2024-02-01

74 papers	2,459 citations	279798 23 h-index	206112 48 g-index
74 all docs	74 docs citations	74 times ranked	2435 citing authors

#	Article	IF	Citations
1	Optimizing Anti-TNF-Î± Therapy: Serum Levels of Infliximab andÂAdalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2016, 14, 550-557.e2.	4.4	312
2	Levels of Drug and Antidrug Antibodies Are Associated With Outcome of Interventions After Loss of Response to Infliximab or Adalimumab. Clinical Gastroenterology and Hepatology, 2015, 13, 522-530.e2.	4.4	268
3	The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab. Gut, 2014, 63, 1258-1264.	12.1	266
4	Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima. Gut, 2016, 65, 1132-1138.	12.1	148
5	Vedolizumab in IBDâ€“Lessons From Real-world Experience; A Systematic Review and Pooled Analysis. Journal of Crohn's and Colitis, 2018, 12, 245-257.	1.3	119
6	Association of Vedolizumab Level, Anti-Drug Antibodies, and Î±4Î²7 Occupancy With Response in Patients With Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2018, 16, 697-705.e7.	4.4	103
7	Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab. Alimentary Pharmacology and Therapeutics, 2017, 45, 276-282.	3.7	98
8	Association of Induction Infliximab Levels With Clinical Response in Perianal Crohnâ€™s Disease. Journal of Crohn's and Colitis, 2017, 11, jjw182.	1.3	85
9	Efficacy and Safety of Vedolizumab for Induction of Remission in Inflammatory Bowel Diseaseâ€”the Israeli Real-World Experience. Inflammatory Bowel Diseases, 2017, 23, 404-408.	1.9	84
10	Undetectable antiâ€‹<scp>TNF</scp> drug levels in patients with longâ€‹term remission predict successful drug withdrawal. Alimentary Pharmacology and Therapeutics, 2015, 42, 356-364.	3.7	74
11	Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2016, 43, 1293-1299.	3.7	72
12	Prospective Observational Evaluation of Time-Dependency of Adalimumab Immunogenicity and drug concentrations: the POETIC Study. American Journal of Gastroenterology, 2018, 113, 890-898.	0.4	67
13	Early drug and antiâ€infliximab antibody levels for prediction of primary nonresponse to infliximab therapy. Alimentary Pharmacology and Therapeutics, 2018, 47, 212-218.	3.7	63
14	Effectiveness and safety of Ustekinumab for Crohn's disease; systematic review and pooled analysis of real-world evidence. Digestive and Liver Disease, 2019, 51, 1232-1240.	0.9	59
15	Effectiveness and Safety of Vedolizumab in Anti-TNF-NaÃ¯ve Patients With Inflammatory Bowel Diseaseâ€”A Multicenter Retrospective European Study. Inflammatory Bowel Diseases, 2018, 24, 2442-2451.	1.9	56
16	Advances in the development of new biologics in inflammatory bowel disease. Annals of Gastroenterology, 2016, 29, 243-8.	0.6	41
17	Discontinuation of Infliximab in Patients With Ulcerative Colitis Is Associated With Increased Risk of Relapse: A Multinational Retrospective Cohort Study. Clinical Gastroenterology and Hepatology, 2016, 14, 1426-1432.e1.	4.4	39
18	Molecular Landscape of Anti-Drug Antibodies Reveals the Mechanism of the Immune Response Following Treatment With TNFÎ± Antagonists. Frontiers in Immunology, 2019, 10, 2921.	4.8	38

#	Article	IF	Citations
19	A novel PillCam Crohnâ€™s capsule score (Eliakim score) for quantification of mucosal inflammation in Crohnâ€™s disease. United European Gastroenterology Journal, 2020, 8, 544-551.	3.8	38
20	Vedolizumab is effective and safe in elderly inflammatory bowel disease patients: a binational, multicenter, retrospective cohort study. United European Gastroenterology Journal, 2020, 8, 1076-1085.	3.8	35
21	Severe and Morbid Obesity in Crohn's Disease Patients: Prevalence and Disease Associations. Digestion, 2013, 88, 26-32.	2.3	28
22	Expression of IL-2, IL-17 and TNF-alpha in patients with Crohn's disease treated with anti-TNF antibodies. Clinics and Research in Hepatology and Gastroenterology, 2014, 38, 491-498.	1.5	26
23	Association Between Infliximab Drug and Antibody Levels and Therapy Outcome in Pediatric Inflammatory Bowel Diseases. Journal of Pediatric Gastroenterology and Nutrition, 2018, 67, 507-512.	1.8	25
24	Prevention of Antidrug Antibody Formation to Infliximab inÂCrohn's Patients With Prior Failure of Thiopurines. Clinical Gastroenterology and Hepatology, 2017, 15, 69-75.	4.4	24
25	Infliximabâ€“Tumor Necrosis Factor Complexes Elicit Formation of Anti-Drug Antibodies. Gastroenterology, 2019, 157, 1338-1351.e8.	1.3	24
26	Effectiveness and safety of vedolizumab for maintenance treatment in inflammatory bowel diseaseâ€”The Israeli real world experience. Digestive and Liver Disease, 2019, 51, 68-74.	0.9	24
27	Safety and effectiveness of ustekinumab for induction of remission in patients with Crohnâ€™s disease: A multicenter Israeli study. United European Gastroenterology Journal, 2020, 8, 418-424.	3.8	24
28	Significance of low level infliximab in the absence of anti-infliximab antibodies. World Journal of Gastroenterology, 2015, 21, 1907.	3.3	19
29	Ashkenazi Jewish Origin Protects Against Formation of Antibodies to Infliximab and Therapy Failure. Medicine (United States), 2015, 94, e673.	1.0	16
30	Association of Infliximab Levels With Mucosal Healing Is Time-Dependent in Crohnâ€™s Disease: Higher Drug Exposure Is Required Postinduction Than During Maintenance Treatment. Inflammatory Bowel Diseases, 2019, 25, 1813-1821.	1.9	16
31	Dose optimisation for Loss of Response to Vedolizumabâ€” Pharmacokinetics and Immune Mechanisms. Journal of Crohn's and Colitis, 2021, 15, 1707-1719.	1.3	16
32	Reâ€phrasing the question: A simple tool for evaluation of adherence to therapy in patients with inflammatory bowel disease. United European Gastroenterology Journal, 2017, 5, 880-886.	3.8	15
33	Diffusion-weighted magnetic resonance enterography for prediction of response to tumor necrosis factor inhibitors in stricturing Crohnâ€™s disease. Abdominal Radiology, 2018, 43, 3207-3212.	2.1	15
34	Infliximab clearance decreases in the second and third trimesters of pregnancy in inflammatory bowel disease. United European Gastroenterology Journal, 2021, 9, 91-101.	3.8	14
35	Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an antiâ€tumour necrosis factor. Alimentary Pharmacology and Therapeutics, 2018, 47, 1117-1125.	3.7	13
36	Terminal Ileum Thickness During Maintenance Therapy Is a Predictive Marker of the Outcome of Infliximab Therapy in Crohn Disease. Inflammatory Bowel Diseases, 2020, 26, 1619-1625.	1.9	12

#	Article	IF	Citations
37	Infliximab therapy intensification upon loss of response: Is there an optimal trough level?. Digestive and Liver Disease, 2019, 51, 1106-1111.	0.9	10
38	Propagation of EBV-driven Lymphomatous Transformation of Peripheral Blood B Cells by Immunomodulators and Biologics Used in the Treatment of Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2020, 26, 1330-1339.	1.9	8
39	Pharmacokinetics and Immune Reconstitution Following Discontinuation of Thiopurine Analogues: Implications for Drug Withdrawal Strategies. Journal of Crohn's and Colitis, 2018, 12, 1410-1417.	1.3	7
40	Lower adalimumab trough levels are associated with higher bowel wall thickness in Crohn's disease. United European Gastroenterology Journal, 2020, 8, 167-174.	3.8	7
41	Host transcriptome signatures in human faecal-washes predict histological remission in patients with IBD. Gut, 2022, 71, 1988-1997.	12.1	6
42	Thromboprophylaxis for Hospitalized Patients with Inflammatory Bowel Diseaseâ€"Are We There Yet?. Journal of Clinical Medicine, 2020, 9, 2753.	2.4	5
43	Infliximab levels and antibodies in IBD-related peripheral arthralgia. International Journal of Colorectal Disease, 2020, 35, 1141-1148.	2.2	5
44	Risk of consecutive immunogenic failure in switchers of anti-tumor necrosis factor alpha among patients with inflammatory bowel diseases. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482110686.	3.2	5
45	Letter: can addition of an immunomodulator really reverse antibody formation and loss of response in patients treated with adalimumab? Authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2017, 45, 760-762.	3.7	4
46	Duration of combination therapy and risk of treatment failure in patients with inflammatory bowel disease. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101503.	1.5	4
47	P571 Effectiveness and safety of Ustekinumab for induction of remission in patients with Crohn's disease: a multi-centre Israeli study. Journal of Crohn's and Colitis, 2019, 13, S399-S400.	1.3	3
48	Association of Infliximab and Vedolizumab Trough Levels with Reported Rates of Adverse Events: A Cross-Sectional Study. Journal of Clinical Medicine, 2021, 10, 4265.	2.4	3
49	DOP001 Effectiveness and safety of vedolizumab in anti-TNF naÃ¯ve patients with inflammatory bowel disease: a multicentre retrospective European Crohnâ€™s and Colitis Organisation study. Journal of Crohn's and Colitis, 2018, 12, S029-S030.	1.3	2
50	Prediction of Recurrent Emergency Department Visits among Patients with Crohnâ€™s Disease: A Retrospective Study. Journal of Clinical Medicine, 2020, 9, 3651.	2.4	2
51	Qualitative sonographic assessment of transmural ileal inflammation in Crohnâ€™s disease: a comparison with MRI activity score. European Journal of Gastroenterology and Hepatology, 2021, 33, 961-966.	1.6	2
52	Machine learning for prediction of intra-abdominal abscesses in patients with Crohnâ€™s disease visiting the emergency department. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110531.	3.2	2
53	Reply. Clinical Gastroenterology and Hepatology, 2016, 14, 1509-1510.	4.4	1
54	Infliximab Efficacy and Safety in an Ulcerative Colitis Patient with Systemic Lupus Erythematosus. Journal of Crohn's and Colitis, 2016, 10, 752-753.	1.3	1

#	Article	IF	Citations
55	Predictors of mortality in inflammatory bowel disease patients treated for pneumonia. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482093945.	3.2	1
56	Longâ€term outcome of ulcerative proctitis. United European Gastroenterology Journal, 2020, 8, 847-848.	3.8	1
57	Editorial: is vedolizumab effective for perianal Crohn's disease?. Alimentary Pharmacology and Therapeutics, 2020, 51, 912-913.	3.7	1
58	P381 Factors predicting risk of colectomy in patients receiving first line steroid and second line biologic salvage therapy for Acute Severe Ulcerative Colitis. Journal of Crohn's and Colitis, 2022, 16, i382-i382.	1.3	1
59	COVID-19 in Patients with Inflammatory Bowel Disease: The Israeli Experience. Vaccines, 2022, 10, 376.	4.4	1
60	Adverse Clinical Outcomes among Inflammatory Bowel Disease Patients Treated for Urinary Tract Infection. Journal of Clinical Medicine, 2022, 11, 1359.	2.4	1
61	PTU-072â€…Discontinuation of Infliximab in Patients with Ulcerative Colitis is Associated with Increased Risk of Relapse: A Multinational Retrospective Cohort Study. Gut, 2016, 65, A88-A89.	12.1	0
62	P189 Diffusion-weighted magnetic resonance enterography for prediction of response to tumour necrosis factor inhibitors in stricturing Crohnâ€™s disease. Journal of Crohn's and Colitis, 2018, 12, S194-S194.	1.3	0
63	Letter: doubleâ€dose intensificationâ€”a quick way to reverse antibody formation and loss of response in patients treated with adalimumab. Authors reply. Alimentary Pharmacology and Therapeutics, 2019, 49, 822-823.	3.7	0
64	P221 Thromboembolic events in hospitalised patients with inflammatory bowel disease â€“ a large tertiary hospital experience. Journal of Crohn's and Colitis, 2020, 14, S253-S253.	1.3	0
65	P643 Development of quantitative ultrasonographic activity score in ileal Crohnâ€™s disease. Journal of Crohn's and Colitis, 2020, 14, S532-S533.	1.3	0
66	P160 A novel PillCam Crohnâ€™s capsule score (Eliakim score) for quantification of mucosal inflammation in Crohnâ€™s disease. Journal of Crohn's and Colitis, 2020, 14, S218-S219.	1.3	0
67	P402 Prediction of emergency department re-visit among Crohnâ€™s disease patients: a retrospective study. Journal of Crohn's and Colitis, 2020, 14, S372-S372.	1.3	0
68	P122 Machine learning for prediction of intra-abdominal abscesses in patients with Crohnâ€™s disease visiting the emergency department. Journal of Crohn's and Colitis, 2021, 15, S214-S214.	1.3	0
69	P275 Course of COVID-19 in patients with Inflammatory Bowel Diseases treated with biologics: the Israeli experience. Journal of Crohn's and Colitis, 2021, 15, S307-S308.	1.3	0
70	Infliximab discontinuation in patients with ulcerative colitis. The Lancet Gastroenterology and Hepatology, 2021, 6, 412-413.	8.1	0
71	Differential serum-intestinal dynamics of infliximab and adalimumab in inflammatory bowel disease patients. Journal of Crohn's and Colitis, 2021, , .	1.3	0
72	P192 First event of acute intestinal inflammation and the risk of progression to Inflammatory bowel disease: a retrospective analysis. Journal of Crohn's and Colitis, 2022, 16, i254-i255.	1.3	0

#	Article	IF	Citations
73	P484 Do vedolizumab trough levels predict response to consecutive therapy in Inflammatory Bowel Disease?. Journal of Crohn's and Colitis, 2022, 16, i451-i451.	1.3	0
74	Delaying an infliximab infusion by more than 3 days is associated with a significant reduction in trough levels but not with clinical worsening. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482210833.	3.2	0